Merck signs agreement to buy Acceleron Pharma for $11.5bn
As agreed, Merck’s subsidiary will commence a tender offer for the purchase of shares of Acceleron for $180 per share. Following completion of deal, this subsidiary of Merck
As agreed, Merck’s subsidiary will commence a tender offer for the purchase of shares of Acceleron for $180 per share. Following completion of deal, this subsidiary of Merck
TRV027 is being evaluated as a potential therapy for treating acute lung injury that leads to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients suffering
AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m. Alexion had entered into a partnership with Caelum
Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir). Avigan/Reeqonus is a broad-spectrum oral antiviral, which is currently being assessed
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Saphnelo (anifrolumab) to treat adult patients with systemic lupus erythematosus (SLE). SLE is a serious autoimmune
UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China. Orismilast is a next-generation PDE4 inhibitor
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases. Axatilimab is an
Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology. The randomised Phase I trial,
The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH). The drug received approval as
The World Health Organization (WHO) has added Regeneron Pharmaceuticals and Roche’s Covid-19 antibody drug cocktail to the list of treatments for Covid-19 patients. The agency has recommended the